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Background: Matrix metalloproteinase-3 (MMP-3) plays an important role in the pathology of rheumatoid arthritis
(RA) and ankylosing spondylitis (AS). Measurement of active MMP-3 in clinical samples could provide information
about progression of rheumatoid diseases, and potentially response to treatment. Hence, we aimed to develop a
sensitive assay specifically measuring the active form of MMP-3 (act-MMP-3) both in ex vivo models and in human sera.
Methods: A monoclonal antibody against the first 6 amino acids of act-MMP-3 was developed, and the specificity was
carefully tested by comparing total and active MMP-3. A technically robust act-MMP-3 ELISA was produced. For
biological validation, human synovial membrane and human cartilage explant (HEX) culture models were measured
and compared by ELISA and immunoblots. For clinical relevance, the serum levels of act-MMP-3 in AS and RA patients
before and after anti-TNF-α treatment were evaluated.
Results: A highly specific and technically robust ELISA detecting act-MMP-3 in serum was developed. The lower limit
of detection was 33.7 pg/mL. The dilution and spiking recovery of human serum was within 100 ± 20%. The average
intra- and inter-assay variations were 3.1% and 13.5% respectively.
High levels of act-MMP-3 expression were observed in human synovial membrane culture and oncostatin M and TNF-α
stimulated human cartilage. In a cross-sectional study of both AS and RA patients, serum act-MMP-3 level was correlated
with C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). In addition, in patients receiving anti-TNF-α
treatment, the serum level of act-MMP-3 was significantly reduced compared to baseline level reflecting the
anti-inflammatory effects of the treatment.
Conclusion: We have successfully developed an assay measuring act-MMP-3 in human serum showing correlation
to inflammatory markers. Further studies are required to clarify, whether act-MMP-3 can serve as a predictive
marker for outcome in chronic rheumatoid disorders.
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Ankylosing spondylitis (AS) is a chronic inflammatory
rheumatic disease, which primarily affects the spine and
sacroiliac joints [1]. Rheumatoid arthritis (RA) is another
chronic autoimmune disease with progressive synovial
joint destruction. Increased turnover of extracellular matrix
(ECM) proteins has been found in both AS and RA, and* Correspondence: ssu@nordicbioscience.com
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unless otherwise stated.the MMPs are known to be important proteases respon-
sible for ECM protein degradation [2]. Previous studies
have indicated MMP-3 as a pathological mediator in AS,
as well as RA [3,4].
The pathology of RA includes different cells of the
joint such as chondrocytes, T cells, fibroblast-like synovio-
cytes and macrophages, features which also are seen in
AS. Among them, fibroblast-like synoviocytes are thought
to be key players in RA [5,6], and they are known to ex-
press MMP-3, which is linked to their ability to cleave
aggrecan, collagen type II, IX, X, link proteins and others. This is an Open Access article distributed under the terms of the Creative
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MMPs, such as pro-MMP-1, pro-MMP-8, pro-MMP-9
and pro-MMP-13 [9-12], and hence MMP-3 is considered
an important pathological mediator of AS and RA.
MMP-3 is composed of a signal peptide, which is
cleaved off during the secretion process, a pro-domain,
which is cleaved during the activation process, a catalytic
domain which has a conserved zinc-binding site, a hinge
domain, and a hemopexin domain [13]. Pro-MMP-3 is
secreted to the ECM in its latent form and is then acti-
vated by removal of the pro-peptide, which is mediated
by serine proteases, plasmin and trypsin [14,15].
Serum levels of MMP-3 have been reported elevated in
RA patients compared with osteoarthritis patients [16], and
to be associated with the development of structural damage
in RA patients [17]. Furthermore, serum MMP-3 levels at
baseline were shown to be predictive of radiographic pro-
gression in an RA cohort [18]. In AS, MMP-3 was also
found to be a predictor of structural progression [19]. Col-
lectively, the line of data underscores the pathological rele-
vance of MMP-3 in arthritic diseases. In addition, elevated
MMP-3 expression has been observed in isolated synovium
and cartilage [20,21].
Presently, two methods are used to measure serum
levels of MMP-3, and these measure either total MMP-3
protein [22] or the activity of MMP-3 using a substrate;
however, neither of these approaches provides specific
information about the active form of MMP-3. It is known
that the cleavage capacity of MMP-3 is regulated by three
levels: synthesis, activation and inhibition. Only act-MMP-
3 has the ability to cleave ECM proteins, while the concen-
tration of latent form only reflects the potential of MMP-3
to degrade proteins. So act-MMP3 may provide other in-
formation beyond total MMP-3, like the activation of pro-
MMP3, and the abnormal imbalanced binding between
act-MMP3 and inhibitors in rheumatoid diseases. More-
over, it is also useful in drug screening process which can
show the treatment efficiency on reducing active protease.
Since pro-MMP3 concentration is much higher than act-
MMP3 in biological fluid, this information may have been
masked by total MMP3 measurement. So in this study we
focused on developing an ELISA specifically detecting
active MMP-3, and we characterized it using both ex vivo
cultures of human cartilage and synovium, and serum
samples from AS and RA cohorts.
Methods
Reagents
All the reagents used in this study were standard high
quality chemicals from Sigma (St.Louis, MO, USA) and
Merck (Whitehouse Station, NJ, USA) unless specifically
mentioned. All the peptides for monoclonal antibody
development were a) immunogenic peptide: FRTFPG
IPKW-GGC b) screening peptide: FRTFPGIPKW-biotinc) standard peptide: FRTFPGIPKW d) elongated pep-
tide: HFRTFPGIPKW. All the peptides were purchased
from the Chinese Peptide Company, China.
Development of monoclonal antibody
All the mice were specific pathogen free (SPF) animals
and housed in SPF animal facility with 12 h light/dark
cycle. The mice had free access to food and water. All the
work on mice was approved by Beijing laboratory animal
administration office and animal ethics committee of
Nordic Bioscience (Beijing).
We used the first 10 amino acids of the N-terminal
(100’FRTFPGIPKW’109) as the immunogenic peptide to
generate specific neo-epitope monoclonal antibodies. The
methods used for monoclonal antibody development were
as previously described [23]. Briefly, six Balb/c mice (female,
4 to 6 weeks old) were immunized subcutaneously with
200 μl emulsified antigen and 60 μg of KLH conjugated
immunogenic peptide. Consecutive immunizations were
performed at two-week intervals in Freund's incomplete
adjuvant, until stable sera titer levels were reached, and
the mice were bled from the 3rd immunization on. At
each bleeding, the serum titer was detected and the mouse
with highest antiserum titer and the best native reactivity
was selected for fusion. The selected mouse was rested for
1 month followed by intravenous boosting with 50 μg of
KLH conjugated immunogenic peptide in 100 μl 0.9%
sodium chloride solution 3 days before isolation of the
spleen for cell fusion.
The fusion procedure has been described [24]. Briefly,
the spleen cells from the immunized mouse with best
antiserum titer and native reactivity were fused with SP2/
0 myeloma fusion partner cells. The fusion cells were
raised in 96-well plates and incubated in a 5% CO2 incu-
bator. Here standard limited dilution was used to promote
monoclonal growth. After seven to ten days of culture, su-
pernatants were screened in a competitive ELISA setting.
Cell lines specific to standard peptide and without cross-
reactivity to elongated peptide were selected and sub-
cloned. At last the antibodies were purified.
In vitro Activation of MMP-3
10 μg of Pro-MMP-3 (cat.no PF063, Calbiochem) was dis-
solved in 100 μL MMP buffer (100 mM Tris-HCl, 100 mM
NaCl, 10 mM CaCl2, 2 mM Zn acetate, pH 8.0). 1 μg pro-
MMP-3 was mixed with 1.1 μL 10 mM APMA and incu-
bated at 37°C for 3 hours.
Ex vivo Synovial membrane tissue culture
Synovial membrane was obtained from total knee re-
placements of osteoarthritis patients at Gentofte Hos-
pital, Gentofte, Denmark. The study was approved by the
Ethics Committee of the Capital Region of Denmark, DK-
3400 (approval no. HD-2007-0084). Patients were informed
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Synovial membrane was isolated during surgery and
kept in DMEM+ 10% FCS at 4°C until the next day,
where experiments were initiated. Synovial membrane
was washed 5 times in PBS to limit contamination and
to remove excess blood. The synovial membrane was di-
vided into equal pieces (explants) of about 30 mg and
placed in a 96 well plate. Explants for the metabolic in-
active (MI) group were inactivated by three freeze–thaw
cycles. They were placed in a 37°C water bath for 5 min,
then immediately transferred to liquid nitrogen and stayed
for another 5 min, and repeated for 3 times. The explants
was cultured in DMEM:F12 for 14 days, where medium
was changed every second or third day. Conditioned
medium was kept at -20°C until analysis.
Human cartilage explants (HEX) culture
The human cartilage explants (HEX) culture was per-
formed as described previously [25]. Briefly, human car-
tilage was collected from cartilage replacement surgery.
The study was approved by the Ethics Committee of
the Capital Region of Denmark, DK-3400 (approval no.
HD-2007-0084). The cartilage explants (16 ± 4 mg) were
placed in 96-well plates and cultured at 37°C, 5% CO2 in-
cubator. Each explant was cultured in 200 μL of DMEM
for 21 days and divided into two groups: 1) without
catabolic factors (W/O), 2) with the catabolic cytokines
oncostatin M (10 ng/mL) and TNF-α (20 ng/mL) (O +T)
to stimulate MMP activity. The culture medium was
changed every 2-3 days and the supernatant was collected
and stored in -20°C for further use.
Western blotting
Synovial membrane culture supernatant, HEX super-
natant and act-MMP-3 were separated by SDS-PAGE, and
proteins were transferred onto nitrocellulose membranes.
The membranes were blocked with 5% skim milk powder
in TBS-T buffer, and incubated in room temperature for
2 hours. The membranes were incubated with primary
antibody at 4°C overnight, followed by three times wash in
TBS-T buffer. Then the membranes were incubated in the
secondary peroxidase conjugated antibody, and followed
by three times wash. Finally, the results were visualized
with ECL detection system (cat# RPN2109, Amersham
Pharmacia). The antibody recognizes both pro and active
form of MMP-3 was from Abcam (ab38916).
Active MMP-3 assay protocol
ELISA-plates used for the assay development were Strep
tavidin-coated from Roche cat.: 11940279. All ELISA plates
were analyzed with ELISA reader from Molecular Devices,
SpectraMax M, (CA, USA). The selected monoclonal anti-
body 7B2 was labeled with horseradish peroxidase (HRP)using the Lightning link HRP labeling kit according to
the instructions of the manufacturer (Innovabioscience,
Babraham, Cambridge, UK). A 96-well streptavidin plate
was coated with screening peptide FRTFPGIPKW-biotin
dissolved in coating buffer (50 mM Tris, 137 mM NaCl,
1% BSA, 0.05% Tween-20, 0.36% Bronidox L5, pH 8.0)
and incubated 30 minutes at 20°C. 30 μL of standard pep-
tide or sample dissolved in incubation buffer (50 mM Tris,
137 mM NaCl, 1% BSA, 0.05% Tween-20, 0.36% Bronidox
L5, 5% liquid II, pH 8.0) were added to appropriate wells,
and followed by 100 μL of conjugated antibody 7B2-HRP.
Synovial membrane culture and HEX culture supernatant,
serum samples measured in the ELISA were pre-diluted
1:2; act-MMP-3 and pro-MMP-3 inhibition test was per-
formed in a serial dilution with the concentration from
1 ng/ul. Then the assay was allowed to incubate at 4°C
for 20 ± 1 hours. Finally, 100 μL tetramethylbenzinidine
(TMB sens) (Kem-En-Tec cat.4850E) was added and the
plate was incubated 15 minutes at 20°C in the dark. All
the above incubation steps included shaking at 300 rpm.
After each incubation step the plate was washed five
times in washing buffer (20 mM Tris, 50 mM NaCl,
pH 7.2). The TMB reaction was stopped by adding 100 μL
of stopping solution (0.1% H2SO₄) and measured at 450 nm
with 650 nm as the reference. A standard curve was per-
formed by serial dilution of the standard peptide with the
concentration of 0, 4.88, 9.77, 19.53, 39.06, 78.13, 156.25,
312.5, 625, 1250, 2500 and 5000 pg/mL. Calibration curve
was plotted using a 4-parametric mathematical fit model.
Technical evaluation
The intra- and inter-assay variation was determined by
10 independent runs of 8 quality control (QC) samples
consisting of serum, and each run consisting of double
determinations of the samples. The lower limit of detec-
tion (LLOD) was determined from 21 zero samples (in-
cubation buffer) and calculated as the mean 3x standard
deviation. Dilution recovery was calculated as a percent-
age of recovery of diluted QC samples from the 100%
sample. Spike recovery was calculated by comparing dif-
ferent concentrations of human cartilage explants super-
natant in incubation buffer and in human serum. Finally,
for each assay, a master calibrator prepared from syn-
thetic peptides accurately quantified by amino acid ana-
lysis was used for calibration purposes.
Clinical samples
Serum samples from 201 AS patients and 47 control RA
patients were analyzed [26]. Of all the patients, 142 AS
patients and 47 RA patients received 3 months anti-
TNF-α treatment after recruitment. At baseline, the Bath
AS Disease Activity Index (BASDAI) and the modified
Stoke AS Spine Score (mSASSS) were recorded for all
the AS patients, while DAS and HAQ were recorded for
Figure 1 7B2 has specific reactivity towards act-MMP-3. (A) Reaction towards to standard peptide and elongated peptide of selected
monoclonal antibody 7B2. (B) Competitive ELISA results of act-MMP-3 and pro-MMP-3. (C) Western blot results of in vitro activated MMP-3 using
7B2 as primary antibody.
Table 1 Technical performance of act-MMP-3 assay
Measurements Technical characteristics
Lower limit of detection 33.7 pg/mL
Intra-assay variability 3.1%
Inter-assay variability 13.5%
Dilution recovery Within 100 ± 20%
Spiking recovery Within 100 ± 20%
Sun et al. BMC Musculoskeletal Disorders 2014, 15:93 Page 4 of 8
http://www.biomedcentral.com/1471-2474/15/93RA patients. CRP (C-reactive protein) concentration and
ESR (erythrocyte sedimentation rate) were also recorded
for both AS and RA patients. For those patients who
have received anti-TNF-α drug, the characteristics men-
tioned above, except for mSASSS, were also recorded
after treatment. In 118 AS patients, mSASSS were re-
corded after 2 years of followup. All the clinical character-
istics used have previously been published by Bay-Jensen
AC et al [26]. Serum samples were thawed from -80°C
storage and act-MMP-3 concentrations were measured
both at baseline and after treatment. The study was ap-
proved by local ethics committee and all patients provided
the written informed consent.
Statistics
Mean values and standard error of the mean (SEM) were
calculated using GraphPad Prism, version 6 (GraphPad
Software, San Diego, CA, USA). Act-MMP-3 differences
between female and male were analyzed using non-
parametric Mann–Whitney test. Correlations between act-
MMP-3 and patient clinical characteristics (age, disease
duration, CRP, ESR, BASDAI, mSASSS) were determined
by Spearman’s test. Significant differences of clinical sam-
ples between pre-treatment and post-treatment were deter-
mined using the Wilcoxon matched-pairs signed rank test.
Significant differences were considered if P < 0.05.Results
Assessment of antibody performance using the pro and
active form MMP-3
When measured in the competitive act-MMP-3 assay
applying the 7B2 antibody, the antibody specifically recog-
nized the N-terminal peptide 100’FRTFPGIPKW’109 and
activated MMP-3 but did not recognize the elongated pep-
tide 99’HFRTFPGIPKW’109 and pro-MMP-3 (Figure 1A,B).
The results were confirmed by western blot of in vitro acti-
vated MMP-3. Bands were detected at 45 kD and 28 kD,
but not at 52 kD, which is the size of the pro-MMP-3. All
three bands were detected by the antibody recognizing the
total MMP-3 antibody (Figure 1C). To ensure the specificity
of the blot, primary antibody incubation was done including
either the elongated peptide or the standard peptide. The
signal was completely blocked only in the presence of the
standard peptide.
Figure 2 Act-MMP-3 profile in human synovial membrane culture. (A) Act-MMP-3 expression in synovial membrane culture supernatant.
(B) Western blot results of synovial membrane culture.
Table 2 Univariate correlation between clinical
parameters and serum act-MMP-3 level in AS patients
Baseline active MMP3 (pg/ml)
R P N
Age (years) -0.05 0.55 173
Disease duration (years) -0.03 0.68 168
CRP (mg/dl) 0.42 <0.0001 167
ESR (mm/hour) 0.38 <0.0001 171
Baseline BASDAI 0.06 0.46 171
Baseline mSASSS 0.10 0.25 130
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The LLOD of the ELISA was 33.7 pg/mL. The average
intra- and inter-assay variations were 3.1% and 13.5%,
respectively. The dilution and spiking recovery of human
serum were within 100 ± 20% (Table 1). The data con-
firms technically robustness of the assay.
Assessment of antibody performance using material from
human synovial membrane and cartilage ex vivo cultures
We investigated the act-MMP-3 expression and release
in human synovial membrane and HEX cultures, and as
expected act-MMP-3 was expressed by human synovial
membrane, compared to the negative control MI group
(Figure 2A). The data was confirmed by western blot-
ting, which again confirmed that the antibody only rec-
ognized the active form of MMP-3 (Figure 2B).
In HEX culture, stimulation with the pro-inflammatory
cytokines TNF-α and oncostatin M resulted in the release
of act-MMP-3 into culture medium starting from the early
culture stage (see Additional file 1: Figure S1), supporting
the pathological relevance of act-MMP-3 in inflammatory
joint diseases.
Act-MMP-3 levels in serum are related to inflammatory
status in AS and RA
We investigated the association between baseline act-
MMP-3 levels and age, gender, disease duration in AS
patients. The data showed that age and disease duration
were not correlated to act-MMP-3 levels (R = -0.046 and
R = -0.032, respectively). Act-MMP-3 levels in male and
female patients were not significantly different. We also
assessed the correlation between baseline act-MMP-3
levels, baseline mSASSS, baseline BASDAI, baseline CRP
and baseline ESR in AS patients (Table 2). Act-MMP-3levels were not correlated with the disease burden markers,
mSASSS and BASDAI (R = 0.10 and R = 0.06, respectively),
but were significantly correlated to CRP and ESR (R = 0.42
and R = 0.38, respectively, P < 0.001), which are markers of
inflammation. Similar data were obtained in samples from
RA patients, with baseline serum act-MMP-3 levels sig-
nificantly correlated to CRP, but with no correlation with
disease activity score (DAS) and health assessment ques-
tionnaire score (HAQ) (see Additional file 1: Table S1).Baseline act-MMP-3 levels predict anti-inflammatory
response to anti-TNF-α treatment
To evaluate if baseline act-MMP-3 level had any predict-
ive value response to anti-TNF-α treatment, correlations
between baseline act-MMP-3 level, BASDAI reduction
(change < 0), CRP reduction (change < 0) and ESR reduc-
tion (change < 0) in AS patients were analyzed (Table 3).
The data showed that baseline act-MMP-3 levels were sig-
nificantly and positively correlated to the reduction in CRP
and ESR (R = 0.44 and R = 0.39, respectively, P < 0.001).
There were no significant correlations between baseline
Table 3 Univariate correlation between clinical
characteristics change after treatment and serum
act-MMP-3 level in AS patients
Baseline active MMP-3 (pg/ml)
R P N
CRP 0.44 <0.0001 107
Reduction (mg/dl)
ESR 0.39 <0.0001 113
Reduction (mm/hour)
BASDAI reduction 0.10 0.26 120
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parable results were observed for the RA patients. Base-
line act-MMP-3 level did not predict DAS and HAQ
change, but were correlated to CRP and ESR changes
(see Additional file 1: Table S2).
To investigate if act-MMP-3 level can predict 2-year
radiographic progression, correlation between baseline
act-MMP-3 level and 2-year mSASSS increase (change > 0)
were analyzed. There was no significant correlation be-
tween baseline act-MMP-3 level and 2-year mSASSS
change (R = 0.07).Serum levels of act-MMP-3 are reduced by anti-TNF-α
treatment
To investigate if act-MMP-3 levels responded to anti-
TNF-α treatment, we measured serum levels of act-MMP-
3 in AS and RA patients at baseline and after anti-TNF-α
treatment. A significant decrease in serum act-MMP-3
after treatment (Figure 3) was observed for both AS and
RA, which showed the anti-TNF-α treatment, could ef-
fectively reduce act-MMP-3 levels, which correlates well
with the previous findings that act-MMP-3 reflects the in-
flammatory status of the patients.Figure 3 Act-MMP-3 assay measured in AS and RA patients at baselin
decreased after anti-TNF-α treatment in (A) AS patients (n = 98) and (B) RADiscussion
MMP-3 is considered an important protease in joint dam-
age where it has been shown to cleave a series of ECM pro-
teins [7,8]. Monitoring act-MMP-3 levels is limited by the
present commercial assays, which cannot distinguish the
pro-form and act-form MMP-3. This illustrates a need for
an assay that specifically measures act-MMP-3, and which
can be used in ex vivo models and in clinical samples.
In this study, we successfully produced a monoclonal
antibody specifically recognizing act-MMP-3, while no
cross-reactivity to an elongated peptide with one more
amino acid at the N-terminal. Additionally, the antibody
only detected act-MMP-3 and not pro-MMP-3, clearly
confirming the specificity of the antibody. Furthermore,
the antibody recognized both forms of act-MMP-3, namely
the 45 kD and 28 kD forms, as expected since the low Mw
form is generated by a C-terminal truncation [14,27].
We applied two ex vivo models to clarify the patho-
logical relevance of MMP-3 expression. As expected from
literature [28,29], we found high levels of act-MMP-3 in
both synovial membrane culture and in Oncostatin M and
TNF-α stimulated human cartilage explants, when com-
pared to controls.
In RA and AS patients, we successfully measured act-
MMP-3, and we found the concentration significantly
decreased after anti-TNF-α treatment, which could indi-
cate that act-MMP-3 could be used as a predictor of the
treatment efficiency at the level of anti-inflammatory ef-
fects, whereas the levels did not correlate to or predict
changes in disease activity scores. Furthermore, act-MMP-3
significantly correlated with CRP and ESR levels, which
showed act-MMP-3 is a marker of inflammation. In previ-
ous studies, CRP, ESR correlated to mSASSS or BASDAI in
AS patients [4,19] and CRP weakly correlated to 2-years’
mSASSS change [19], which indicate act-MMP-3 behaves
different than the classical inflammatory markers.e and after treatment. The concentration of act-MMP-3 significant
patients (n = 41). (** = P < 0.01, **** = P < 0.0001).
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mSASSS change [19]; however, we did not reproduce this
data, which could be explained by two reasons. Firstly, the
AS patients in the previous study did not receive anti-
TNF-α treatment. Secondly, an MMP-3 assay which mea-
sured both pro-MMP-3 and act-MMP-3 was used in the
previous study, while in our study we only measured act-
MMP-3. We found act-MMP-3 only correlated with the
inflammation markers CRP and ESR, but not to other
measures of disease burden in AS (BASDAI, mSASSS) and
RA (DAS, HAQ), and hence it appears that act-MMP-3
reflects other aspects of disease than total MMP-3.
However, there are some limitations to consider in re-
lation to the detection of act-MMP-3 in human serum.
Active forms of MMPs are known to bind to carrier pro-
teins like TIMP and α-2 macroglobulin (α2M) which are
abundant in biological fluid [30,31]. α2M is a tetramers
assembled by four 180 kD subunits, which can capture act-
MMPs and shield them in the subunits [32], and this could
skew the levels in serum towards lower levels. Further-
more, the interaction between α2M and act-MMP-3 is co-
valent and thereby virtually impossible to break without
destroying antigen-antibody reaction. This could be the ex-
planation for the low concentrations of free act-MMP-3
detected in human serum. Importantly, even at very low
levels act-MMP-3 still has pathological relevance.Conclusions
In summary, we have developed a highly sensitive and
reproducible assay monitoring act-MMP-3 level in serum
from humans. In ex vivo models, we confirmed act-MMP-3
can be expressed by synovial membrane and oncostatin M
and TNF-α stimulated human cartilage. Furthermore, we
found act-MMP-3 in human serum showing correlation to
inflammatory markers. Further studies are required to clar-
ify, whether act-MMP-3 can serve as a predictive marker
for outcome in chronic rheumatoid disorders.Additional file
Additional file 1: Includes one figure and two tables. Figure S1 is
act-MMP-3 measurement in the supernatant of HEX culture. Table S1 is
the univariate correlation between clinical parameters and serum act-MMP3
level in RA patients. Table S2 is the univariate correlation between clinical
characteristics change after treatment and serum act-MMP-3 level in
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